, Volume 105, Issue 2, pp 197–203 | Cite as

Influence of different benzodiazepines on the experimental morphine abstinence syndrome

  • R. Maldonado
  • J. A. Micó
  • O. Valverde
  • M. C. Saavedra
  • I. Leonsegui
  • J. Gibert-Rahola
Original Investigations


The abuse of benzodiazepines by narcotic addicts has been well documented. However, the pharmacological basis of this abuse is not clear. In this study the effects of different benzodiazepines (flunitrazepam: 0.5, 1 and 2 mg/kg; nitrazepam: 0.5, 1, 2.5, 5 and 10 mg/kg; diazepam: 0.5, 1, 2.5, 5 and 10 mg/kg; chlordiazepoxide: 0.5, 1, 2.5, 5 and 10 mg/kg; and triazolam: 0.5, 1 and 2 mg/kg) on the morphine withdrawal syndrome in mice have been compared. Drugs were administered 30 min before naloxone-induced withdrawal. All benzodiazepines tested induced similar changes in some of the signs of morphine abstinence: decreased jumping behavior and increased wet dog shake frequency. Jumping behavior was particularly decreased by triazolam and wet dog shakes were mainly increased by flunitrazepam and nitrazepam. Forepaw treading was reduced by flunitrazepam, diazepam and triazolam, increased by nitrazepam and not changed by chlordiazepoxide. Tremor was effectively reduced by diazepam but less reliably by the other benzodiazepines. Teeth chattering was reduced by flunitrazepam and diazepam. These results indicate that benzodiazepines can interfere with the expression of the morphine withdrawal syndrome.

Key words

Benzodiazepine Morphine withdrawal Flunitrazepam Nitrazepam Diazepam Chlordiazepoxide Triazolam 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antonelli T, Beani L, Bianchi C, Rando S, Simonatto M, Tanganelli S (1986) Cortical acetylcholine release is decreased and gamma-aminobutyric acid outflow is reduced during morphine withdrawal. Bri J Pharmacol 89:853–860Google Scholar
  2. Ary M, Cox B, Lomax P (1977) Dopaminergic mechanisms in precipitated withdrawal in morphine-dependent rats. J Pharmacol Exp Ther 200:271–276PubMedGoogle Scholar
  3. Baldino F, Cowan A, Geller EB, Adler M (1979) Effects of antipsychotic and antianxiety drugs on the morphine abstinence syndrome in rats. J Pharmacol Exp Ther 208:63–66PubMedGoogle Scholar
  4. Berthold H, Borel JF, Fluckiger E (1989) Enigmatic action of ciclosporine A on the naloxone-precipitated morphine withdrawal syndrome in mice. Neuroscience 31:97–103CrossRefPubMedGoogle Scholar
  5. Bläsig J, Herz K, Reinhold K, Zieglgansberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33:19–38CrossRefPubMedGoogle Scholar
  6. Bruno F, Ferracuti F (1982) Descrizione di alcuni casi clinici di abuso e di possibile dipendenza da flunitrazepam. Riv Tossicol Sperim Clin 12:125–152Google Scholar
  7. Buccafusco JJ, Masshall DC, Turner RM (1984) A comparison of the inhibitory effects of clonidine and guanfacine on the morphine withdrawal in rats. Life Sci 35:1401–1409CrossRefPubMedGoogle Scholar
  8. Contreras E, Tamayo L (1985) Effects of ethylendiamine on morphine analgesia and tolerance-dependence in mice. Gen Pharmacol 16:529–531PubMedGoogle Scholar
  9. Contreras E, Tamayo L, Quijada L (1979) Effects of GABA-transaminase upon some morphine effects. Neuropharmacology 18:309–313CrossRefPubMedGoogle Scholar
  10. Cooper SJ (1983) Benzodiazepine-opiate antagonist interactions in relation to anxiety and appetite. TIPS 4:456–458Google Scholar
  11. Drummond DC, Turkington D, Rahman MZ, Mullin J, Jackson P (1989) Chlordiazepoxide vs methadone in opiate withdrawal: a preliminary double blind trial. Drug Alcohol Depend 23:63–72CrossRefPubMedGoogle Scholar
  12. Duka T, Wuster M, Herz A (1980) Benzodiazepines modulate striatal enkephalin levels via a GABAergic mechanism. Life Sci 26:771–776CrossRefPubMedGoogle Scholar
  13. Evans SM, Schwartz GE, Griffiths RR (1989) Zolpidam and triazolam in humans: behavioral effects and abuse liability. Abstracts of 28th meeting of American College of Neuropsychopharmacology, 161Google Scholar
  14. Gibert-Rahola J, Maldonado R, Micó JA, Leonsegui I, Saavedra MC (1988) Comparative study in mice of flunitrazepam vs diazepam on morphine withdrawal syndrome. Prog Neuropsychopharmacol Biol Psychiatry 12:927–933CrossRefPubMedGoogle Scholar
  15. Gold MS, Byck R, Sweeny DR, Kleber HD (1979) Endorphin-locus coeruleus connection mediates opiates action and withdrawal. Biomedicine 30:1–4PubMedGoogle Scholar
  16. Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV (1985) Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 9:133–151CrossRefPubMedGoogle Scholar
  17. Haefely W, Polc P (1983) Electrophysiological studies on the interactions of anxiolytics drugs with GABAergic mechanisms. In: Malik JB, Enna SJ, Yamamura HI (eds), Anxiolytics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 113–145Google Scholar
  18. Hynes MD, Shearman GT, Lal H (1980) Alterations in brain GABA fail to influence morphine withdrawal body shakes. Brain Res Bull 5:805–808CrossRefGoogle Scholar
  19. Khana NC, Sharma SK (1983) Megadoses of vitamin-C prevent the development of tolerance and physical dependence on morphine mice. Life Sci 33 [suppl I] 401–404CrossRefGoogle Scholar
  20. Lee EHY, Wang FB, Tang YP, Geyer MA (1987) GABAergic interneurons in the dorsal raphe mediate the effects of apomorphine on serotonergic system. Brain Res Bull 18:345–353CrossRefPubMedGoogle Scholar
  21. Litt I, Colli A, Cohen M (1971) Diazepam in the management of heroin withdrawal in adolescent; preliminary report. Pediat Pharmacol Ther 78:692–696Google Scholar
  22. Llorens C, Maitres M, Bardry M, Schwartz J (1978) Hypersensitivity to noradrenaline in cortex after chronic morphine: relevance to tolerance and dependence. Nature 274:603–605CrossRefPubMedGoogle Scholar
  23. Maldonado R, Daugé V, Callebert J, Villete J, Feger J, Fournié-Zaluski M-C, Roques BP (1989) Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome. Eur J Pharmacol 165:199–207CrossRefPubMedGoogle Scholar
  24. Micó JA, Maldonado R, Saavedra MC, Leonsegui I, Gibert-Rahola J (1987) Comparative strategies in the development of morphine withdrawal behaviour in mice: effects of benzodiazepines and antidepressants. 1st Congress of Preclinical Strategies in Psychopharmacology, ParisGoogle Scholar
  25. Marks J (1985) The benzodiazepine: use, overuse, misuse, abuse? MTP Press, Lancaster, England, pp 1–165Google Scholar
  26. Marshall I, Weinstock M (1971) Quantitative method for assessing one symptom of the withdrawal syndrome in mice after chronic morphine administration. Nature 234:223–224CrossRefPubMedGoogle Scholar
  27. Nathenson G, Golden GS, Litt IP (1971) Diazepam in the management of the neonatal narcotic withdrawal syndrome. Pediatrics 48:523–527PubMedGoogle Scholar
  28. Navaratman V (1982) Impact of scheduling drugs under the 1971 convention on psychotropic substances-benzodiazepines reappraised. United Nations Research and Training Centre in Drug Dependence, National Drug Research Centre. Univ. Science Malasy Minden, Penang, MalaysiaGoogle Scholar
  29. Nicolai P, Di Carlo M, Alfani F, Cerbo R, Smeriglio M, Borgo S, Cipriani E, Tarquini S, Malizia E (1981) La nostra experienza sull intossicacione acuta da flunitracepam. Riv Tossicol Sperim Clin 3:47Google Scholar
  30. Sawynok J (1984) GABAergic mechanisms in antinociception. Prog Neuropsychopharmacol. Biol Psychiatry 8:581–586CrossRefPubMedGoogle Scholar
  31. Sivam SP, Ho IK (1983) GABAergic drugs, morphine and morphine tolerance. A study in relation to nociception and gastrointestinal transit in mice. Neuropharmacology 22:767–774CrossRefPubMedGoogle Scholar
  32. Sivam SP, Ho IK (1984) GABA in morphine analgesia and tolerance. Life Sci 37:199–208CrossRefGoogle Scholar
  33. Smith RB, Kroboth PD, Varner PD (1987) Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 27:971–979PubMedGoogle Scholar
  34. Sugerman AA, Mikstal MW, Freymuth HW (1971) Comparison of prazepam and placebo in the treatment of convalescing narcotic addicts. J Clin Pharmacol 11:383–387Google Scholar
  35. Tseng L-F, Loh HH, Wei T (1975) Effects of clonidine on morphine withdrawal signs in the rat. Eur J Pharmacol 30:93–99CrossRefPubMedGoogle Scholar
  36. Ushijima J, Mizuki Y, Yamada M, Glaving G (1985) Neuronal mechanisms involved in drug-induced jumping behavior in mice. Eur J Pharmacol 112:225–229CrossRefPubMedGoogle Scholar
  37. Valeri P, Martinelli B, Pimpinella G, Severini C (1989) Effects of dapiprazole, clonidine and yohimbine on the development of dependence and withdrawal behaviour in mice. Drug Alcohol Depend 23:73–77CrossRefPubMedGoogle Scholar
  38. Wei E, Loh HH, Way EL (1973) Quantitative aspects of precipitated abstinence in morphine-dependent rats. J Pharmacol Exp Ther 184:398–403PubMedGoogle Scholar
  39. Williams D, Thorn B (1984) Opiate withdrawal behavior after focal brain stimulation. Pharmacol Biochem Behav 21:699–705PubMedGoogle Scholar
  40. Woody GE, O'Brien CP, Greenstein R (1975) Misuse and abuse of diazepam: an increasingly common medical problem. Int J Addict 10:843–848PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • R. Maldonado
    • 1
  • J. A. Micó
    • 1
  • O. Valverde
    • 1
  • M. C. Saavedra
    • 1
  • I. Leonsegui
    • 1
  • J. Gibert-Rahola
    • 1
  1. 1.Department of Neuroscience and ToxicologyLaboratory of Neuropsychopharmacology, School of MedicineCádizSpain

Personalised recommendations